<div id="readability-page-1"><p>Amdocs Limited (NASDAQ:DOX - Free Report) - Equities research analysts at Zacks Research reduced their Q1 2026 EPS estimates for Amdocs in a research note issued to investors on Wednesday, December 10th. Zacks Research analyst Team now forecasts that the technology company will post earnings of $1.54 per share for the quarter, down from their prior estimate of $1.62. The consensus estimate for Amdocs' current full-year earnings is $6.21 per share. Zacks Research also issued estimates for Amdocs' Q3 2026 earnings at $1.64 EPS, Q4 2026 earnings at $1.71 EPS, FY2026 earnings at $6.48 EPS, Q2 2027 earnings at $1.72 EPS, Q3 2027 earnings at $1.75 EPS, FY2027 earnings at $6.92 EPS and FY2028 earnings at $7.36 EPS.</p><p>Other analysts have also recently issued reports about the company. Wall Street Zen cut Amdocs from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. Wolfe Research  restated a &#34;peer perform&#34; rating on shares of Amdocs in a research report on Thursday, November 13th. Weiss Ratings  reaffirmed a &#34;hold (c)&#34; rating on shares of Amdocs in a research note on Thursday, October 30th. Bank of America dropped their price target on shares of Amdocs from $100.00 to $97.00 and set a &#34;buy&#34; rating for the company in a research note on Wednesday, November 12th. Finally, Stifel Nicolaus reduced their price target on shares of Amdocs from $100.00 to $97.00 and set a &#34;buy&#34; rating on the stock in a research report on Wednesday, November 12th. Two analysts have rated the stock with a Buy rating and two have assigned  a Hold rating to the company. Based on data from MarketBeat.com, Amdocs  has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $97.00.</p><p><b>Read Our Latest Stock Report on Amdocs</b></p><h2>Amdocs Price Performance</h2><p>NASDAQ:DOX opened at $79.35 on Monday. Amdocs has a one year low of $74.32 and a one year high of $95.41. The stock has a market cap of $8.96 billion, a PE ratio of 15.71, a P/E/G ratio of 1.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.22 and a current ratio of 1.17. The stock has a 50 day moving average price of $80.21 and a 200 day moving average price of $85.21. </p><p>Amdocs (NASDAQ:DOX - Get Free Report) last released its quarterly earnings data on Tuesday, November 11th. The technology company reported $1.83 EPS for the quarter, beating analysts' consensus estimates of $1.82 by $0.01. The company had revenue of $1.15 billion during the quarter, compared to the consensus estimate of $1.15 billion. Amdocs had a net margin of 12.46% and a return on equity of 19.78%. Amdocs's quarterly revenue was down 9.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.70 EPS. Amdocs has set its FY 2026 guidance at 7.270-7.550 EPS and its Q1 2026 guidance at 1.730-1.790 EPS. </p><h2>Amdocs Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be given a dividend of $0.527 per share. This represents a $2.11 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, December 31st. Amdocs's dividend payout ratio (DPR) is currently 41.78%. </p><h2>Institutional Investors Weigh In On Amdocs</h2><p>Several institutional investors and hedge funds have recently modified their holdings of the company. Allworth Financial LP boosted its holdings in  Amdocs by 9.3% during the 3rd quarter. Allworth Financial LP now owns 2,570 shares of the technology company's stock valued at $211,000 after acquiring an additional 218 shares during the period.  CIBC Private Wealth Group LLC lifted its position in shares of  Amdocs by 190.2% during the third quarter. CIBC Private Wealth Group LLC now owns 595 shares of the technology company's stock worth $49,000 after purchasing an additional 390 shares in the last quarter.  CIBC Bancorp USA Inc. purchased a new position in shares of  Amdocs in the third quarter valued at approximately $502,000.  Caitong International Asset Management Co. Ltd grew its holdings in shares of  Amdocs by 68.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 795 shares of the technology company's stock valued at $65,000 after purchasing an additional 323 shares in the last quarter.  Finally, Advisory Services Network LLC acquired a new position in shares of  Amdocs in the third quarter valued at approximately $42,000. Hedge funds and other institutional investors own  92.02% of the company's stock. </p><h2>Amdocs Company Profile</h2> (Get Free Report)<p>Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.</p><h2>See Also</h2><ul><li>Five stocks we like better than Amdocs</li><li>What Are Dividend Achievers? An Introduction</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>Stock Sentiment Analysis: How it Works</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>Investing in the High PE Growth Stocks </li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9Y?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RE9Y"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amdocs Right Now?</h2><p>Before you consider Amdocs, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.</p><p>While Amdocs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Zacks Research has lowered its Q1 2026 EPS estimates for Amdocs from $1.62 to $1.54. The consensus full-year earnings estimate is $6.21 per share. Other analysts have issued mixed ratings, with a consensus rating of "Moderate Buy" and an average price target of $97.00. Amdocs' recent quarterly earnings beat estimates slightly, with a reported EPS of $1.83. The company also announced a quarterly dividend of $0.527 per share.</p>

Zacks Research Issues Negative Outlook for Amdocs Earnings